Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

PartnershipPRO-XTEN® Dual-masked T-cell EngagersPositive

AI Analysis

Summary

Vir Biotechnology and Gilead Sciences have entered a multi-program collaboration and license agreement to discover and develop novel PRO-XTEN® dual-masked T-cell engagers for treating solid tumors.

Importance:7/10

Sentiment:

0.60

CollaborationLicensingOncologyT-cell EngagersSolid Tumors

Related Companies

$GILD

Read the original article

Published by yahoo_finance on October 14, 2026 12:30 PM

Read Original